TA186: Rheumatoid arthritis - certolizumab pegol
This is a discussion on TA186: Rheumatoid arthritis - certolizumab pegol within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Rheumatoid arthritis - certolizumab pegol. It links to the published guidance and key ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
04-01-2010, 12:51 PM
|
|||
|
|||
TA186: Rheumatoid arthritis - certolizumab pegol
The summary for the published technology appraisal on Rheumatoid arthritis - certolizumab pegol. It links to the published guidance and key documents.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA126: Rheumatoid arthritis (refractory) - rituximab | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA186: Rheumatoid arthritis - certolizumab pegol | industry_news | Updates from the Technology Assessment Authorities | 0 | 02-23-2010 08:40 PM |
| Blood Test May Predict Rheumatoid Arthritis | industry_news | Other Clinical Pharmacy News | 0 | 01-29-2010 05:49 PM |
| Certolizumab Maintains Efficacy for 2 Years in Rheumatoid Arthritis Patients | industry_news | Other Clinical Pharmacy News | 0 | 10-31-2008 11:15 PM |
| Risk of MI Doubled in Patients With Rheumatoid Arthritis | industry_news | Other Clinical Pharmacy News | 0 | 10-10-2008 07:19 PM |
© 2008 DrugManagementForum™ powered by |
 |